Companies will be looking for small molecules that interact with and inhibit dipeptidyl peptidase I.
Unizyme Laboratories in Denmark and SARomics in Sweden entered a research service collaboration related to inflammatory diseases. The aim is to discover novel lead compounds targeting dipeptidyl peptidase I (DPPI; cathepsin C).
Unizyme will focus on identifying new small molecules that interact with and inhibit the function of DPPI. SARomics will apply its expertise in structure-based drug design to assist in the development of lead compounds.
SARomics will also facilitate the interpretation of 3-D structures of DPPI interacting with small molecules provided by Unizyme. This information will be combined with high-speed computational methods, like high-performance ligand-receptor docking, to accelerate lead molecule identification.
